Esther Ooi

Dr, BSc PhD W.Aust., MBiostat Syd.

  • The University of Western Australia (M704), 35 Stirling Highway,

    6009 Perth


  • 1636 Citations
  • 25 h-Index

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Roles and responsibilities

Current Positions:

2015 - Heart Foundation Future Leader Fellow; School of Medicine and Pharmacology, UWA
2013 – Invited Visiting Researcher; Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University

Previous Positions:

2005 Teaching Intern; School of Medicine and Pharmacology, UWA
2007 Unilever Postdoctoral Fellow; School of Medicine and Pharmacology, UWA; Unilever Colworth, UK
2008 – 2009 National Heart Foundation Postdoctoral Research Fellow; School of Medicine and Pharmacology, UWA
2008 – 2010 Development and Communication of Research Course Controller, UWA
2008 – 2010 Masters of Clinical Research Coordinator, UWA
2010 A & A Saw Medical Research Fellowship, UWA
2010 – 2012 Visiting Postdoctoral Research Fellow, Jean Mayer USDA Human Nutrition Research Center on Ageing, Tufts University, Boston MA, USA
2010 – 2012 Visiting Postdoctoral Research Fellow, Department of Nutrition, Harvard University, Boston MA, USA
2010 – 2014 National Health and Medical Research Council (NHMRC) CJ Martin Early Career Fellow; School of Medicine and Pharmacology, UWA

Funding overview

Current Funding:

Pathophysiology and Therapeutic Regulation of Lipid Disorders in Subjects at High Cardiovascular Disease Risk; NHF Future Leader Fellowships (2015-2018) [CIA]
Lipoprotein(a) metabolism in subjects at high risk of cardiovascular disease; NHMRC Project Grant ($668,434; 2014-16) [CIA]

Pervious Funding:

Reducing cardiovascular risk in the metabolic syndrome and type 2 diabetes: novel approaches to studies of lipoprotein metabolism; NHMRC Project Grant ($527,275; 2008-9) [AI]
Novel approaches to studies of lipoprotein metabolism; NHMRC training fellowship ($336,170; 2010-2014) [CIA]
Niacin reduces Lp(a) in type 2 diabetes; NHMRC Project Grant ($354,920; 2012-14) [CID]

Coordinated regulation and function of apoC-III in obesity; NHF Grant-In-Aid ($98,788; 2008-9) [AI]
National Heart Foundation Postdoctoral Fellowship ($131,500; 2008-9) [CIA]
ApoC-III as a regulator of fatty acid and lipoprotein metabolism in women: understanding dyslipidemia as a cardiovascular risk factor; NHF Grant-In-Aid ($127,404; 2008-9) [CIC]

Raine Medical Research Foundation
A systems biology approach to study the coordinate regulation and function of apolipoprotein C-III in the metabolic syndrome; Raine Priming Grant ($183,361; 2008-9) [CIA]

University of Western Australia
A & A Saw Medical Research Fellowship ($145,074; 2010-11)[CIA]
Kinetic Defects in Lipoprotein Metabolism in Patients with Chronic Renal Failure; UWA Research Grant (A$27,600; 2008) [CIA]

Royal Perth Hospital Medical Research Foundation
ApoC-II as a regulator of fatty acid and lipoprotein metabolism in women: understanding dyslipidemia as a cardiovascular risk factor, Medical Research Foundation Grant ($16,500; 2013) [CIA]


My vision for the next 4 years is to establish and undertake a dynamic, innovative research program focused on a new CVD risk factor, lipoprotein(a) [Lp(a)], a quantitative genetic trait that independently raises the risk of premature cardiovascular disease, which directly impacts clinical care of patients in cardiometabolic services at Perth hospitals. The significance and relevance of my research program is underscored by the knowledge that dyslipidemia, a consequence of abnormal lipid and lipoprotein regulation, is a powerful causal risk factor for cardiovascular disease, a leading cause of death in Australia. New knowledge from my research will impact on treatment strategies for dyslipidemia and consequently, cardiovascular risk.
Overarching research interest: Pathogenesis, diagnosis and treatment of hyperlipidemias, atherosclerosis and cardiovascular disease.
Specific research interest: Metabolic studies; the application of stable isotope tracer methods to study the physiology and pathophysiology of lipoprotein metabolism in humans. These include studies of the role of therapeutic, dietary and lifestyle interventions in the regulation of the lipoprotein system in healthy individuals and populations at high-risk of cardiovascular disease (obesity, type 2 diabetes, non-alcoholic liver disease, genetic hyperlipidemias).

Research expertise keywords

  • Lipid metabolism
  • Systems biology

Fingerprint Dive into the research topics where Esther Ooi is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 9 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Open Access
  • Association Between Plasma Neutrophil Gelatinase-Associated Lipocalin and Cardiac Disease Hospitalizations and Deaths in Older Women

    Chong, J. J. H., Prince, R. L., Thompson, P. L., Thavapalachandran, S., Ooi, E., Devine, A., Lim, E. E. M., Byrnes, E., Wong, G., Lim, W. H. & Lewis, J. R., 8 Jan 2019, In : Journal of the American Heart Association. 8, 1, p. e011028

    Research output: Contribution to journalArticle

    Open Access
  • 4 Citations (Scopus)
  • 1 Citation (Scopus)
  • 2 Citations (Scopus)



    • 1 Editorial activity

    Nutrition, Metabolism and Cardiovascular Diseases (Journal)

    Esther Ooi (Reviewer)

    Activity: Editorial work or peer review of publicationsEditorial activity